Author: Vikas Kumar
31 May 2022
Anxiety and Depression is the most common psychological disorder around the world and a huge population is suffering from these disorders. Depression is a situation where the sad mood lasts for a long time and affects the functioning of the regular functioning whereas anxiety is considered as the feelings of fear, nervousness, and worry — from time to time.
Thus, increasing awareness about mental health disorders and the rising demand to treat such disorders is fueling growth in the anxiety and depression treatment market. Therefore, the global anxiety and depression treatment market is projected to expand significantly with a CAGR of 3% from 2021 to 2027. Moreover, the increasing investment in the research and development of effective medications increases the market opportunities for the anxiety and depression treatment market.
For a detailed analysis of the COVID-19 imoact browse through https://univdatos.com/report/anxiety-and-depression-treatment-market/
Due to the COVID-19 pandemic, governments of several countries, worldwide, have implemented strong measures, such as lockdowns and social distancing, to ensure health threats. Quite evidently, manufacturers across the world, including those of anxiety and depression treatment products, have been negatively impacted by the economic crisis triggered by the pandemic. Additionally, the supply of raw materials has been severely affected, by the restrictions imposed by the governments on domestic and international trade, which leads to the disruption in the supply chain. Thus, it has further affected the production of active pharmaceutical ingredients (APIs) and raw materials for such drugs and devices, which has hampered the growth of the anxiety and depression treatment market.
For a detailed analysis of the anxiety and depression treatment browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=20559
Based on drug type, the market is segmented into antidepressants, anticonvulsants, atypical antipsychotics, benzodiazepines, and Beta-blockers. Among them, the antidepressant drug market is expected to witness significant growth during the forecast period. This is due to the increasing number of depression cases and related disorders. Furthermore, the antidepressant drug also class deals with the different symptoms of depression such as insomnia, stress, and anxiety and it is a driving factor for the significant market share of the segment in the forecast period.
Based on the distribution channel, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Amongst them, the online channel segment is witnessing a lucrative CAGR due to increasing internet penetration and mobile phone users. A total of 5 billion people around the world are using the internet accounting for 63% of the global population and it continues to grow. In the last 12 months from April 2021 to April 2022, the 200 million new users connected to the internet. Furthermore, the heavy discounts on online medicines offered by the companies are also responsible for the increasing market size of the segment in the anxiety and depression treatment market.
Based on the disorder type, the market is segmented into major depressive disorder (MDD), OCD, phobia, PTSD, and others. Among them, the market is expected to witness significant growth due to major depressive disorder. MDD results in poor quality of life and overall decreased productivity and can increase suicidal cases. Furthermore, the large portion of the adults affected by the disorder raises concerns for the governments and healthcare institutions to provide better treatment for the disorder. As per NIMH, 19.4 million adults, or 7.8 percent of all adults in the United States have suffered from a major depressive disorder.
Request for Sample of the report browse through https://univdatos.com/get-a-free-sample-form-php/?product_id=20559
For a better understanding of the market adoption of the anxiety and depression treatment, the market is analyzed based on its worldwide presence in the countries such as North America (United States, Canada, and the Rest of North America), Europe (Germany, France, Italy, Spain, United Kingdom, and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America constitutes a major market for the anxiety and depression treatment industry owing to the increasing number of depression cases and rising lifestyle-associated stress in the region. Furthermore, growth in awareness regarding mental health, high-disposable income, and an increase in the number of prescriptions for antidepressants is further expected to drive the market.
GlaxoSmithKline plc, Pfizer, Inc., Eli Lilly and Company, H. Lundbeck A/S, Forest Laboratories, Inc., AstraZeneca, Merck & Company, Inc., Johnson & Johnson, Sanofi-Aventis, and Lupin ltd. are some of the key players operating in the global Anxiety and Depression Treatment market. Several M&As along with partnerships have been undertaken by these players to develop various types of Anxiety and Depression Treatment devices.
Global Anxiety and Depression Treatment Market Segmentation
Market Insight, by Drug Type
Market Insight, by Distribution Channel
Market Insight, by Disorder Type
Market Insight, by Region
Top Company Profiles
Get a call back
